Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of FBR-002 in hospitalized adults with COVID-19 requiring supplemental oxygen
2021-002390-25Phase 2Completed
- Sponsor
- Fabentech
- Start
- Dec 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anti SARS-CoV-2 equine hyperimmune serum in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Fabentech. Primary endpoint: Safety and tolerability through Day 14. Started Dec 2021; status: completed.
02
Drugs
anti SARS-CoV-2 equine hyperimmune serum
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002390-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002390-25.